Kinetic Concepts buys skin-graft startup; Sigma-Aldrich plans to restructure;

 @FierceMedDev: Spread the word - we're highlighting some of the top M&A targets in devices and diagnostics. Special Report | Follow @FierceMedDev

 @MarkHFierce: Could the device tax lead to supply problems? Item | Follow @MarkHFierce

 @DamianFierce: The SEC says employees of Stryker, Celgene and Sanofi carried on a complex insider trading scam. Report | Follow @DamianFierce

> Kinetic Concepts quietly bought up skin-graft startup MoMelan Technologies, a source tells Xconomy. News

> Medtronic ($MDT) CEO Omar Ishrak echoed the industry-wide concern about the impending device tax, but, when it comes to repeal, the company prefers "to focus on things we can control" and is assuming it will have to eat the charge come 2013. Report

> Devicemaker Vasomedical ($VASO) deepened its losses to $2.5 million in the last quarter as revenue dropped 12.4% to $5.72 million. More

> Thermo Fisher ($TMO) has inked a long-term license agreement with Fujirebio, planning to make the company's biomarker assay Procalcitonin available on the Thermo's diagnostic platforms. Item

> Starting in January, Sigma-Aldrich ($SIAL) will reorganize its business in thirds, separating diagnostics, research and custom manufacturing. News

> Columbia University researchers have developed a score-based system for determining whether patients are suited for stenting. Article

> The FDA is moving up the deadline for devicemakers to comply with its new unique device ID system. Story

> SQI Diagnostics says it's exploring the idea of merging or going up for sale. Report

Biotech News

 @FierceBiotech: GSK's new Promacta approval triggers a spike for Ligand shares. News | Follow @FierceBiotech

 @JohnCFierce: Celgene, Sanofi execs in (another) biopharma insider trading case. Is it that hard for insiders to get away with this? Story | Follow @JohnCFierce

 @RyanMFierce: Rare disease R&D and academic/pharma tie-up trends have melded in Shire's new alliance with Boston Children's. More | Follow @RyanMFierce

> Overnight success proves elusive for oral MS drugs. Item

> Review scolds FDA for lingering problems recruiting fresh talent. Story

Pharma News

@FiercePharma: New special report for a short week: The world's 20 best-selling generic drugs. Not just the usual suspects. Special Report | Follow @FiercePharma

> Bayer says trumping Reckitt's $1.4B Schiff bid is too rich. Story

> Overnight success proves elusive for oral MS drugs. News

> Sanofi, Celgene execs charged in insider trading ring. Article

Biotech Research News

> Stem cells: A future treatment for Type 1 diabetes? News

> Northwestern U nanoparticle treats MS in mice. Article

> Radioactive injectable polymer safely kills tumors in mice. Story

> High risk of Alzheimer's disease linked to newly discovered gene mutation. Report

Pharma Manufacturing News

> Hikma temporarily closing West-Ward plant to fix new issues. Item

> Catalent cuts 45 at U.K. plant as demand 'changes'. Article

> Manufacturers return some drugs to market but shortages persist. News

> Feds probe if FedEx, UPS are delivery vehicles for illegal online pharmacies. Story